By dampening inflammation-driven indoleamine-2,3-dioxygenase (IDO) activity, these interventions may preserve tryptophan availability for serotonin synthesis, reducing neurotoxic kynurenine metabolites that have been implicated in depression and fatigue [42]. The gene discussed is IDO1; the disease is depressive symptom measurement.